Cardiovascular endocrinology: Is ANGPTL3 the next PCSK9?

Screen-Shot-2017-07-14-at-1.26.53-PM

Is ANGPTL3 the next PCSK9? Recent reports suggest that molecular therapies targeting ANGPTL3 and its encoded protein angiopoietin-like protein 3 have clinical potential comparable to therapies targeting PCSK9 and its encoded protein proprotein convertase subtilisin/kexin type 9. By mainly affecting triglyceride-rich lipoproteins, ANGPTL3 inhibition might prove complementary to LDL cholesterol lowering with PCSK9 blockade.

Leave a Comment